Drug intelligence / Profile preview

PMS-006

Development stage: Preclinical
Lead developer: Qingdao Primedicine Pharmaceutical

Overview

PMS-006 is a preclinical-stage drug candidate under development by Qingdao Primedicine Pharmaceutical. It is currently in the early experimental phase, targeting central nervous system (CNS) conditions including anxiety disorders, epilepsy, and sleep disorders. While the developer's scientific platform focuses on targets such as AMPA receptors, NMDA receptors, SREBP-1, and JNK, the specific molecular target and modality for PMS-006 have not been publicly disclosed. As of 2024, the asset remains in the earliest stages of development, preceding formal pharmaceutical research and IND-enabling studies.

Beyond the preview

Go deeper on PMS-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMS-006.

Explore the full profile